Molecular basis of juvenile myelomonocytic leukemia
- PMID: 20139388
- PMCID: PMC2817017
- DOI: 10.3324/haematol.2009.016865
Molecular basis of juvenile myelomonocytic leukemia
Figures
Comment on
-
Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.Haematologica. 2010 Feb;95(2):320-3. doi: 10.3324/haematol.2009.010355. Epub 2009 Dec 16. Haematologica. 2010. PMID: 20015894 Free PMC article.
References
-
- Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106(4):1027–32. - PubMed
-
- Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of Tumours of Haematopoietic and Lymphoid tissues. IARC Press; Lyon: 2001. World Health Organization classification of tumours.
-
- EWOG-MDS. Clinical Trial Protocol EWOG-MDS 2006. Prospective non-randomized multi-center study for epidemiology and characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood. 2007
-
- Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood. 1997;89(10):3534–43. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
